January
Guilford Launches U.S. Marketing Program for AGGRASTAT® Injection

February
NIH Begins Phase II Clinical Testing of GPI 1485 for Parkinson's disease



February
Guilford initiates a Phase II clinical trial of AQUAVAN® Injection in the United States

FDA approves expanded use of GLIADEL Wafer during initial surgery for primary malignant brain cancer.

May
Guilford signs license agreement with Pfizer for novel NAALADase Inhibitor Technology

June
Guilford issues $60 million of 5% convertible notes.

September
Research Grants Totaling $5.7 Millin Awarded for Evaluation of Guilford Technologies.

October
Guilford Complete Patient Enrollment for Phase II Clinical Trial of GPI 1485 in Parkinson's Disease.

November
Guilford Announces Positive Phase II Clinical Trial Results of AQUAVAN® Injection.

Guilford Begins Phase II Clinical Trial of GPI 1485 for Post-Prostatectomy Erectile Dysfunction.




January
Guilford signs European licensing agreement for DOPASCAN® Injection

February
Guilford announces management changes; David P. Wright appointed President and Chief Business Officer

March
Guilford receives FDA review letter for GLIADEL® Wafer

June
Guilford activates investigational new drug application and begins first U.S. study of AQUAVAN® Injection

July
Guilford starts European phase II clinical trial of AQUAVAN® Injection

September
Guilford reports positive results with neuroimmunphilin ligands in models of post-prostatectomy erectile dysfunction

November
Guilford initiates Phase II clinical trial of GPI 1485 for the treatment of patients with Parkinson's disease

December
NIH selects GPI 1485 for neuroprotective study of Parkinson's disease




January
Guilford raises $46 million under its shelf registration

June
GLIADEL® Wafer receives priority review for first line therapy application

Guilford announces private placement of $59 million of common stock

July
Guilford announces completion of NIL-A phase II clinical trial for Parkinson's disease

September
Guilford regains exclusive worldwide rights to neuroimmunophilin ligand program from Amgen

December
FDA Advisory Committee believes GLIADEL® Wafer provides clinical benefit with acceptable safety in patients with newly diagnosed malignant glioma




February
Guilford licenses novel discovery from Johns Hopkins University

March
Guilford acquires exclusive worldwide rights to novel pro-drug of Propofol, one of the world’s best selling anesthetic agents

August
Guilford announces start of phase II study in Parkinson’s Disease and receipt of new patent covering neuroimmunophilin ligands

October
Guilford reacquires commercial rights to GLIADEL® Wafer – first localized treatment for malignant brain cancer

November
Guilford announces phase III clinical trial results for GLIADEL® Wafer in first-line treatment of malignant glioma



June
GLIADEL® Wafer receives favorable opinion for marketing authorization in ten European countries

August
Amgen and Guilford announce start of neuroimmunophilin clinical trials

September
Guilford completes $45 million private placement of common stock

December
Guilford announces receipt of Amgen milestone payment for IND filing for neuroimmunophilin compound

Guilford announces IND filing of new polymer-oncology candidate, PACLIMER® Microspheres




January
Multinational Phase III clinical trial of GLIADEL® Wafer begins for newly diagnosed patients with malignant glioma

December
Guilford receives international health authority approvals for GLIADEL® Wafer in Canada and France




February
Rhône-Poulenc Rorer launches GLIADEL® Wafer in the US

April
Guilford completes $75 million public offering of common stock

August
Amgen enters into agreement with Guilford for Neuroimmunophilin Ligand Program




January
Guilford announces corporate partnership with Daiichi Radioisotopes Ltd. for DOPASCAN® Injection

March
Guilford completes $46 million public offering of common stock

June
Guilford signs worldwide marketing agreement for GLIADEL® Wafer with Rhône-Poulenc Rorer (excludes Scandinavia and Japan)

September
Guilford receives FDA marketing clearance for GLIADEL® Wafer for recurrent surgery




March
Guilford completes manufacturing facility for GLIADEL® Wafer

August
Guilford completes $19.5 million public offering of common stock

October
Guilford receives clearance for GLIADEL® Wafer Treatment IND

November
Guilford signs GLIADEL® Wafer collaboration with Orion-Pharma

December
Guilford announces GLIADEL® Wafer Phase III European trial results




June
Guilford completes IPO




July
Guilford Pharmaceuticals Inc. founded




Copyright© 2004 Guilford Pharmaceuticals Inc.
Legal Information